TY - JOUR
T1 - Toward personalized treatment of hallucinations
AU - Sommer, Iris E.
AU - Kleijer, Hidde
AU - Hugdahl, Kenneth
N1 - Funding Information:
The current work was supported by a Fellowship and a VIDI grant from the Netherlands Organization for Health Research and Development (ZonMW) to I.E.S., grant number 017106301, ‘Where the voices come from, and how to get rid of them, and ERC Advanced Grant number 693124, RCN NORMENT number 213363, RCN FRIMEDBIO number 221550 and Helse-Vest number 912045 and 911793 to Kenneth Hugdahl.
Funding Information:
The current work was supported by a Fellowship and a VIDI grant from the Netherlands Organization for Health Research and Development (ZonMW) to I.E.S., grant number 017106301, 'Where the voices come from, and how to get rid of them, and ERC Advanced Grant number 693124, RCN NORMENT number 213363, RCN FRIMEDBIO number 221550 and Helse-Vest number 912045 and 911793 to Kenneth Hugdahl.
Publisher Copyright:
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Purpose of review Hallucinations are common and often stressful experiences, occurring in all sensory modalities. They frequently complicate many disorders or situations, such as Parkinson's disease, schizophrenia, hearing or vision loss, intoxications and delirium. Although psychoeducation, coping techniques and psychotherapy may be broadly applicable, they do not address a specific underlying brain mechanism. Pharmacotherapy may effectively alleviate hallucinations if the corresponding mechanism is present, whereas in its absence, may only cause harmful side effects. Therefore, pharmacotherapy needs input about underlying brain mechanisms. Recent findings Recent findings suggest new underlying neurobiological mechanisms as possible therapeutic targets in selected patients, for example increased glutamate levels. In addition, neuronavigation can guide repetitive transcranial magnetic stimulation treatment of auditory verbal hallucinations to target-specific cortical regions. Summary We propose the use of neuroimaging methods to better understand the interaction of different mechanisms underlying hallucinations and to use this knowledge to guide pharmacotherapy or focal brain stimulation in a personalized manner. In addition, we suggest evidence from various imaging modalities should converge to answer a research question. We believe this 'convergence of evidence' avoids the problem of overreliance on single and isolated findings.
AB - Purpose of review Hallucinations are common and often stressful experiences, occurring in all sensory modalities. They frequently complicate many disorders or situations, such as Parkinson's disease, schizophrenia, hearing or vision loss, intoxications and delirium. Although psychoeducation, coping techniques and psychotherapy may be broadly applicable, they do not address a specific underlying brain mechanism. Pharmacotherapy may effectively alleviate hallucinations if the corresponding mechanism is present, whereas in its absence, may only cause harmful side effects. Therefore, pharmacotherapy needs input about underlying brain mechanisms. Recent findings Recent findings suggest new underlying neurobiological mechanisms as possible therapeutic targets in selected patients, for example increased glutamate levels. In addition, neuronavigation can guide repetitive transcranial magnetic stimulation treatment of auditory verbal hallucinations to target-specific cortical regions. Summary We propose the use of neuroimaging methods to better understand the interaction of different mechanisms underlying hallucinations and to use this knowledge to guide pharmacotherapy or focal brain stimulation in a personalized manner. In addition, we suggest evidence from various imaging modalities should converge to answer a research question. We believe this 'convergence of evidence' avoids the problem of overreliance on single and isolated findings.
KW - brain stimulation
KW - convergence of evidence
KW - hallucinations
KW - personalized treatment
KW - pharmacology
UR - http://www.scopus.com/inward/record.url?scp=85045153585&partnerID=8YFLogxK
U2 - 10.1097/YCO.0000000000000416
DO - 10.1097/YCO.0000000000000416
M3 - Review article
C2 - 29528896
AN - SCOPUS:85045153585
SN - 0951-7367
VL - 31
SP - 237
EP - 245
JO - Current Opinion in Psychiatry
JF - Current Opinion in Psychiatry
IS - 3
ER -